

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

<b>In re United States Patent Application of:</b>	)	<b>Docket No.:</b>	<b>4354-110</b>
	)		
<b>Applicants:</b>	)	<b>Conf. No.:</b>	<b>4322</b>
<b>CABANA, Bernard E., et</b>	)		
<b>al.</b>	)		
	)		
<b>Application No.:</b>	)	<b>Art Unit:</b>	<b>1614</b>
<b>10/668,792</b>	)		
	)		
<b>Date Filed:</b>	)	<b>Examiner:</b>	<b>Spivack, Phyllis G.</b>
<b>September 23, 2003</b>	)		
	)		
<b>Title:</b>	)	<b>Customer</b>	
<b>RIFALAZIL</b>	)	<b>No.:</b>	<b>23448</b>
<b>COMPOSITIONS AND</b>	)		
<b>THERAPEUTIC</b>	)		
<b>REGIMENS</b>	)		

**CERTIFICATE OF EFS FILING**

I hereby certify that this document is being filed via EFS in the United States Patent  
and Trademark Office on **March 29, 2011**.  
*/david bradlin/*

---

**RESPONSE TO OFFICE ACTION IN U.S. PATENT APPLICATION NO.  
10/668,792**

---

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

The following responds to the Office Action mailed in connection with the above-identified application on December 29, 2010. Please amend the claims of the above-identified patent application as set out in **Section I (Amendments to the Claims)**, beginning on page 4 hereof. Remarks concerning the amendments to the claims and the substance of the Office Action are set out in **Section II (Remarks)** hereof.